Autobahn Therapeutics Reports AMPLIFY-BD Results for Elunetirom in Bipolar Depression, Highlighting Rapid, Robust, and Sustained Improvements in Depressive Symptoms and Functioning
Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that full results from its Phase 2 AMPLIFY-BD trial were presented at Psych Congress 2026, which took place September 15-19 in New Orleans, Louisiana. Elunetirom, a novel, oral, once daily, brain-penetrant CNS thyroid hormone receptor agonist, achieved clinically meaningful benefit and statistical significance across the primary and all key secondary depression endpoints in AMPLIFY-BD, evaluating elunetirom as an adjunctive treatment in patients with bipolar I or bipolar II depression. The data support Autobahn’s plans to engage with regulatory agencies on a potential path to registration of elunetirom for bipolar depression, a prevalent disorder affecting approximately 7 million adults in the U.S.
Autobahn Therapeutics Reports New Nonclinical Data Showing Elunetirom Rapidly Builds Synaptic Connections and Restores Cellular Energy Capacity in Neurons
Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today reported new nonclinical data on the antidepressant mechanism of action for elunetirom, its lead investigational therapy in Phase 2 development for adjunctive treatment of bipolar depression and major depressive disorder (MDD). The data show that elunetirom rapidly increased the number of synaptic connections between neurons and enhances the cellular energy machinery that neurons depend on to build and sustain those connections. Together, these findings provide a cellular framework for the rapid onset and robust magnitude of antidepressant effects observed in Autobahn’s Phase 2 AMPLIFY-BD clinical trial in bipolar depression.
Autobahn Therapeutics Reports Positive Phase 2 Topline Data for Elunetirom in Bipolar Depression, Demonstrating Rapid, Robust, and Durable Antidepressant Effects
Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced positive topline data from its Phase 2 AMPLIFY-BD trial evaluating elunetirom as an adjunctive treatment in patients with bipolar I or bipolar II depression, a disorder affecting approximately 7 million adults in the U.S.
Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences
Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that management will participate in the following upcoming investor conferences in June.
Autobahn Therapeutics Announces U.S. FDA Fast Track Designation for Elunetirom, a CNS-Directed Thyroid Hormone Receptor Agonist, for the Adjunctive Treatment of Bipolar Depression
Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to elunetirom, the Company’s lead candidate, for the adjunctive treatment of depressive episodes associated with bipolar I or bipolar II disorder in adults. Elunetirom is an oral, once daily, brain-penetrant, CNS thyroid hormone receptor (CNS-TR) agonist that Autobahn is developing as an adjunctive treatment for bipolar depression and major depressive disorder (MDD).
Autobahn Therapeutics Presents New Preclinical Data at ASCP Annual Meeting Demonstrating Elunetirom Drives Robust Bioenergetic and Neuroplastic Improvements in Neuronal Cultures
Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced the presentation of new preclinical data for elunetirom (ABX-002), the company’s lead asset currently in Phase 2 clinical development for adjunctive major depressive disorder (MDD) and bipolar depression, at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place in Miami Beach, Florida.
